Parasites, Hosts and Diseases

The Korea Society for Parasitology and Tropical Medicine (대한기생충학·열대의학회)
권호 표지
DOI QR코드

DOI QR Code

Seropositivity and Serointensity of Toxoplasma gondii Antibodies and DNA among Patients with Schizophrenia

  • Received : 2014.10.20
  • Accepted : 2014.12.21
  • Published : 2015.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

The aim of this cross sectional case control study was to examine the serofrequency and serointensity of Toxoplasma gondii (Tg) IgG, IgM, and DNA among patients with schizophrenia. A total of 101 patients with schizophrenia and 55 healthy controls from Sungai Buloh Hospital, Selangor, Malaysia and University Malaya Medical Center (UMMC) were included in this study. The diagnosis of schizophrenia was made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). The presence of Tg infection was examined using both indirect (ELISA) and direct (quantitative real-time PCR) detection methods by measuring Tg IgG and IgM and DNA, respectively. The serofrequency of Tg IgG antibodies (51.5%, 52/101) and DNA (32.67%, 33/101) among patients with schizophrenia was significantly higher than IgG (18.2%, 10/55) and DNA (3.64%, 2/55) of the controls (IgG, P=0.000, OD=4.8, CI=2.2-10.5; DNA, P=0.000, OD=12.9, CI=2.17-10.51). However, the Tg IgM antibody between patients with schizophrenia and controls was not significant (P>0.005). There was no significant difference (P>0.005) in both serointensity of Tg IgG and DNA between patients with schizophrenia and controls. These findings have further demonstrated the strong association between the active Tg infection and schizophrenia.

Keywords

References

  1. Cotter DR, Pariante CM, Everall IP. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull 2001; 55: 585-595. https://doi.org/10.1016/S0361-9230(01)00527-5
  2. Fatemi SH, Earle J, Kanodia R, Kist D, Emamian ES, Patterson PH, Shi L, Sidwell R. Prenatal viral infection leads to pyramidal cell atrophy and macrocephaly in adulthood: implications for genesis of autism and schizophrenia. Cell Mol Neurobiol 2002; 22: 25-33. https://doi.org/10.1023/A:1015337611258
  3. Horacek J, Flegr J, Tintera J, Verebova K, Spaniel F, Novak T, Brunovsky M, Bubenikova-Valesova V, Holub D, Palenicek T, Hoschi C. Latent toxoplasmosis reduces gray matter density in schizophrenia but not in controls: voxel-based-morphometry (VBM) study. World J Biol Psychiatry 2012; 13: 501-509. https://doi.org/10.3109/15622975.2011.573809
  4. Carruthers VB, Suzuki Y. Effects of Toxoplasma gondii infection on the brain. Schizophrenia Bull 2007; 33: 745-751. https://doi.org/10.1093/schbul/sbm008
  5. Prandovszky E, Gaskell E, Martin H, Dubey JP, Webster JP, McConkey GA. The neurotrophic parasite Toxoplasma gondii increases dopamine metabolism. PLoS One 2011; 6: e23866. https://doi.org/10.1371/journal.pone.0023866
  6. McConkey GA, Martin HL, Bristow GC, Webster JP. Toxoplasma gondii infection and behaviour-location, location, location? J Exp Biol 2013; 216: 113-119. https://doi.org/10.1242/jeb.074153
  7. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. J Neuropsychiatry Clin Neurosci 1996; 8: 223-226. https://doi.org/10.1176/jnp.8.2.223
  8. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987; 1: 133-152. https://doi.org/10.1002/syn.890010203
  9. Richtand NM, Welge JA, Loque AD, Keck PE Jr, Strakowski SM, McNamara RK. Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 2007; 32: 1715-1726. https://doi.org/10.1038/sj.npp.1301305
  10. Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res 2003; 62: 237-244. https://doi.org/10.1016/S0920-9964(02)00357-2
  11. Webster JP, Lamberton PHL, Donnelly CA, Torrey EF. Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii’s ability to alter host behaviour. Proc Biol Soc 2006; 273: 1023-1030. https://doi.org/10.1098/rspb.2005.3413
  12. Stibbs HH. Changes in brain concentrations of catecholamines and indolamines in Toxoplasma gondii infected mice. Ann Trop Med Parasitol 1985; 79: 153-157. https://doi.org/10.1080/00034983.1985.11811902
  13. Petitto JM, McCarthy DB, Rinker CM, Huang Z, Getty T. Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2. J Neuroimmunol 1997; 73: 183-190. https://doi.org/10.1016/S0165-5728(96)00196-8
  14. Gatkowska J, Wieczorek M, Dziadek B, Dzitko K, Dlugonska H. Sex-dependent neurotransmitter level changes in brains of Toxoplasma gondii infected mice. Exp Parasitol 2013; 133: 1-7. https://doi.org/10.1016/j.exppara.2012.10.005
  15. Flegr J. How and why Toxoplasma makes us crazy. Trends Parasitol 2013; 29: 156-163. https://doi.org/10.1016/j.pt.2013.01.007
  16. Xiao J, Li Y, Prandovszky E, Karuppagounder SS, Talbot CC Jr, Dawson VL, Dawson TM, Yolken RH. MicroRNA-132 dysregulation in Toxoplasma gondii infection has implications for dopamine signaling pathway. Neuroscience 2014; 268: 128-138. https://doi.org/10.1016/j.neuroscience.2014.03.015
  17. Torrey EF, Yolken RH. Toxoplasma gondii and schizophrenia. Emerg Infect Dis 2003; 9: 1375-1380. https://doi.org/10.3201/eid0911.030143
  18. Wang T, Tang ZH, Li JF, Li XN, Wang X, Zhoa ZJ. A potential association between Toxoplasma gondii infection and schizophrenia in mouse models. Exp Parasitol 2013; 135: 497-502. https://doi.org/10.1016/j.exppara.2013.08.012
  19. Wang HL, Xiang YT, Li QY, Wang XP, Liu ZC, Hao SS, Liu X, Liu LL, Wang GH, Wang DG, Zhang PA, Bao AY, Chiu HF, Ungvari GS, Lai KY, Buchanan RW. The effect of artemether on psychotic symptoms and cognitive impairment in first-episode, antipsychotic drug-naive persons with schizophrenia seropositive to Toxoplasma gondii. J Psychiatr Res 2014; 53: 119-124. https://doi.org/10.1016/j.jpsychires.2014.02.016
  20. Torrey EF, Bartko JJ, Lun ZR, Yolken RH. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr Bull 2007; 33: 729-736. https://doi.org/10.1093/schbul/sbl050
  21. Ahmad D, Mehdi S, Sayed HH, Sayed AK, Shizad G. Serological survey of Toxoplasmagondii in schizophrenia patients referred to Psychiatric Hospital, Sari City, Iran. Trop Biomed 2010; 27: 476-482.
  22. Tedla Y, Shibre T, Ali O, Tadele G, Woldeamanuel Y, Asrat D, Aseffa A, Mihret W, Abebe M, Alem A, Medhin G, Habte A. Serum antibodies to Toxoplasma gondii and Herpesvidae family viruses in individuals with schizophrenia and bipolar disorder: a case-control study. Ethiop Med J 2011; 49: 211-220.
  23. Arias I, Sorlozano A, Villegas E, de Dios Luna J, McKenney K, Cervilla J, Gutierrez B, Gutierrez J. Infectious agents associated with schizophrenia: a meta-analysis. Schizophr Res 2012; 136: 128-136. https://doi.org/10.1016/j.schres.2011.10.026
  24. Alvarado-Esquivel C, Urbina-alvarez JB, Estrada-Martinez S, Toress-Castorena A, Molotla-de-Leon G, Liesenfeld O, Dubey JP. Toxoplasma gondii infection and schizophrenia: a case control study in a low Toxoplasma seroprevalence Mexican population. Parasitol Int 2011; 60: 151-155. https://doi.org/10.1016/j.parint.2010.12.003
  25. Cetinkaya ZS, Yazar S, Gecici O, Namli MN. Anti-Toxoplasma gondii antibodies in patients with schizophrenia- preliminary findings in a Turkish sample. Schizophr Bull 2007; 33: 789-791. https://doi.org/10.1093/schbul/sbm021
  26. Niebuhr DW, Millikan AM, Cowan DN, Yolken R, Li Y, Weber NS. Selected infectious agents and risk of schizophrenia among U.S. military personnel. Am J Psychiatry 2008; 165: 99-106. https://doi.org/10.1176/appi.ajp.2007.06081254
  27. Torrey EF, Bartko JJ, Yolken RH. Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr Bull 2012; 38: 642-647. https://doi.org/10.1093/schbul/sbs043
  28. Thomas HV, Thomas DR, Salmon RL, Lewis G, Smith AP. Toxoplasma and Coxiella infection and psychiatric morbidity: a retrospective cohort analysis. BMC Psychiatry 2004; 4: 32. https://doi.org/10.1186/1471-244X-4-32
  29. Xiao Y, Yin J, Jiang N, Xiang M, Hao L, Lu H, Sang H, Liu X, Ankarklev J, Lindh J, Chen Q. Seroepidemiology of human Toxoplasma gondii infection in China. BMC Infect Dis 2010; 10: 4. https://doi.org/10.1186/1471-2334-10-4
  30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-4, 4th ed. Washington DC, USA. American Psychiatric Press. ISBN: 0-89042-062-9. 1994, p 886.
  31. Yolken RH, Dickerson FB, Fuller Torrey E. Toxoplasma and schizophrenia. Parasite Immunol 2009; 31: 706-715. https://doi.org/10.1111/j.1365-3024.2009.01131.x
  32. Hamidinejat H, Ghorbanpoor M, Hosseini M, Alavi SM, Nabavi L, Jalali MHR, Borojeni MP, Jafari H, Mohammadaligol S. Toxoplasma gondii infection in first-episode and inpatient individuals with schizophrenia. Int J Infect Dis 2010; 14: e978-e981. https://doi.org/10.1016/j.ijid.2010.05.018
  33. Pearce BD, Hubbard S, Rivera HN, Wilkins PP, Fisch MC, Hopkins MH, Hasenkamp W, Gross R, Bilwise N, Jones JL, Duncan E. Toxoplasma gondii exposure affects neural processing speed as measured by acoustic startle latency in schizophrenia and controls. Schizophr Res 2013; 150: 258-261. https://doi.org/10.1016/j.schres.2013.07.028
  34. Leweke FM, Gerth CW, Koethe D, Klosterkotter J, Ruslanova I, Krivogorsky B, Torrey EF, Yolken RH. Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 2004; 254: 4-8. https://doi.org/10.1007/s00406-004-0481-6
  35. Tamer GS, Dundar D, Yalug I, Caliskan S, Yazar S, Aker A. The schizophrenia and Toxoplasma gondii connection: infectious, immune or both? Adv Ther 2008; 25: 703-709. https://doi.org/10.1007/s12325-008-0063-5
  36. Juanah LY, Jalaludin J, Osman M, Osman ZJ. Seroprevalence of Toxoplasma gondii among schizophrenics at Hospital Kajang. Am J Infect Dis 2013; 9: 11-16. https://doi.org/10.3844/ajidsp.2013.11.16

Cited by

  1. Mental Health Disorders Associated with Foodborne Pathogens vol.79, pp.11, 2016, https://doi.org/10.4315/0362-028x.jfp-15-587
  2. Possible Link Between Toxoplasma gondii Infection and Mood Disorders in Lorestan Province, Western Iran vol.11, pp.4, 2015, https://doi.org/10.5812/archcid.36602
  3. A Case-Control Seroprevalence Study on the Association Between Toxoplasma gondii Infection and Bipolar Disorder vol.10, pp.None, 2019, https://doi.org/10.3389/fpsyt.2019.00766
  4. Lack of circulating toxoplasma gondii DNA in seropositive patients with bipolar or schizophrenia spectrum disorders vol.273, pp.None, 2019, https://doi.org/10.1016/j.psychres.2019.01.104
  5. Serological and molecular detection of Toxoplasma gondii in terrestrial and marine wildlife harvested for food in Nunavik, Canada vol.12, pp.1, 2015, https://doi.org/10.1186/s13071-019-3408-9
  6. A Review on the Prevalence of Toxoplasma gondii in Humans and Animals Reported in Malaysia from 2008–2018 vol.17, pp.13, 2015, https://doi.org/10.3390/ijerph17134809
  7. Molecular Detection and Genetic Diversity of Toxoplasma gondii Oocysts in Cat Faeces from Klang Valley, Malaysia, Using B1 and REP Genes in 2018 vol.9, pp.7, 2020, https://doi.org/10.3390/pathogens9070576
  8. Cerebral Malaria and Toxoplasmosis: Could their Concomitant Presentation Worsen Psychotic Condition? vol.5, pp.2, 2015, https://doi.org/10.2478/ast-2020-0011
  9. Seroprevalence of ToRCH Pathogens in Southeast Asia vol.9, pp.3, 2015, https://doi.org/10.3390/microorganisms9030574
  10. Association between exposure to toxoplasmosis and major psychiatric disorders: a systematic review vol.43, pp.4, 2021, https://doi.org/10.1590/1516-4446-2020-0904